Sally E. Blount - 29 Apr 2022 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Reporting relationship: Director
Issuer ticker: ABT
Reported as of: 29 Apr 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 May 2022, 17:52:08 UTC
Prior SEC filing: 03 Jun 2021
Next SEC filing: 02 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Sally E. Blount by Jessica H. Paik, Attorney-in-Fact

Key filing fact

Sally E. Blount filed Form 4 for ABBOTT LABORATORIES (ABT) on 03 May 2022.

Key facts

This page summarizes Sally E. Blount's Form 4 filing for ABBOTT LABORATORIES (ABT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 May 2022, 17:52.

Change

Previous filing in this sequence was filed on 03 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABT transaction

Common shares without par value

Award

Transaction value: $0
Shares: +1,602
Change %: +5.4%
Price: $0.000000
Shares after: 31,341
Date: 29 Apr 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).